On March 6, 2026, visitors to peptidesciences.com found three sentences in a red-bordered box on an otherwise blank page:
"After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products."
That was it. No explanation for the closure. No information about outstanding orders. No timeline. Sixteen years of operations, gone in a paragraph — and we're still not entirely sure why.
This is our attempt to lay out what we actually know, separate it from what we're inferring, and say honestly where those two things blur together.
Who they were
Peptide Sciences was, by most measures, the largest gray-market research peptide vendor in the United States. In December 2025, the company was generating approximately $7.4 million in monthly sales across more than 100 compounds — from growth hormone secretagogues like CJC-1295 and Ipamorelin, to tissue repair peptides like BPC-157 and TB-500, to GLP-1 agonists including semaglutide, tirzepatide, and retatrutide. Their site was pulling roughly one million visitors a month. They were not a fringe operation.
We tracked their prices in the Peptide Price Lab data feed. They were consistent, they had a recognizable catalog, and they had been around long enough that "check Peptide Sciences" had become a baseline move for anyone comparing research peptide costs. When they closed, we removed them from our price tracking — which is part of why we felt we owed readers some explanation of what happened.
What we know for certain
The announcement came without warning and without context. There was no raid announced publicly, no criminal complaint filed against the company, and no regulatory action specifically naming Peptide Sciences on the public record. They closed themselves, using the word "voluntarily" — a word that is doing a lot of work in that sentence, and that we'll come back to.
What we can document is the regulatory environment they were operating in when they closed:
In December 2024, the FDA issued warning letters to several research peptide vendors. In February 2025, the FDA declared the semaglutide shortage officially resolved — eliminating the legal justification that compounding pharmacies (and, by extension, vendors claiming research-use status) had been leaning on to sell generic versions of Ozempic and Wegovy. In June 2025, the FDA raided the Amino Asylum warehouse. By September 2025, more than 50 warning letters had been issued targeting gray-market GLP-1 vendors. In December 2025, founders of Paradigm Peptides entered guilty pleas. Tailor Made Compounding settled with a $1.79 million forfeiture. All American Peptide's owners pleaded guilty to conspiracy charges. New legislation — the SAFE Drugs Act — codified what enforcement had already been signaling: selling research chemicals biologically identical to FDA-approved drugs, without a New Drug Application, was not protected by a "for research use only" label.
This is the documented backdrop. Peptide Sciences closed into the middle of it.
There were also quality issues on the public record. Independent third-party testing, published in the months before the shutdown, found significant problems across parts of the Peptide Sciences catalog. Retatrutide — their highest-demand GLP-1 product — received a failing grade across 37 tested samples, with counterfeit detection flagged in November 2025. CJC-1295 and Tesamorelin also received failing scores. Not everything failed: Ipamorelin, PT-141, and BPC-157 scored well. But the failures landed on the products generating the most consumer attention, and on a company whose reputation for quality had been part of its brand.
What we're inferring
Here is where we're honest about the limits of what we know.
No one from Peptide Sciences has publicly explained the decision. There's no lawsuit, no tell-all, no regulatory document that specifically names the company. Everything we know about why they closed is inference from the evidence above — and we want to be clear that inference is what it is.
Our read: they did a math problem and the math didn't work anymore.
GLP-1 products — semaglutide, tirzepatide, retatrutide — had become the highest-margin category in the research peptide market. Research-grade versions sold for $150–$300 versus $900–$1,300 or more for the pharmaceutical brands. That spread was the business. But by early 2026, Eli Lilly had won an International Trade Commission order blocking tirzepatide imports. The FDA had resolved the semaglutide shortage, closing off the compounding justification. The enforcement pressure around GLP-1s specifically was more aggressive than around any other category. Peptide Sciences had reportedly begun removing GLP-1 products from its catalog before the shutdown — a sign that the revenue engine was already being dismantled.
Add quality exposure on the remaining catalog. Add an enforcement environment where two separate vendor principals had just entered guilty pleas. Add the SAFE Drugs Act. Add the pattern of 50+ warning letters and the awareness that the "research use only" shield had, in the words of one healthcare law firm, provided "essentially zero protection" by early 2026.
The word "voluntarily" in the shutdown notice is the key tell. They weren't raided. They weren't named in a public action. They chose to close — which strongly suggests they made a calculated decision that continuing was more legally dangerous than stopping. That's our interpretation, not a confirmed fact. But it's the interpretation the evidence points toward.
What it means
Peptide Sciences wasn't an isolated case. It's the most visible name in a wave of closures that included Amino Asylum, Paradigm Peptides, Science.bio, and others. The model that defined research peptide commerce for a decade — direct-to-consumer sales under a "for research use only" label — is effectively over as a viable commercial structure in the United States.
That does not mean the compounds are going away. In February 2026, HHS Secretary RFK Jr. announced that approximately 14 of the 19 peptides the FDA had placed on its restricted compounding list would be reclassified back to Category 1, restoring compounding pharmacy access with a physician's prescription. The access model is changing; the molecules are not disappearing.
For readers of Peptide Price Lab, the practical implication is this: the gray-market research vendor landscape is smaller than it was, and the vendors still operating are carrying more regulatory risk than they were a year ago. That makes third-party testing documentation — certificates of analysis, published testing results, verifiable purity data — more important as a selection criterion, not less. A vendor that publishes its COAs and undergoes independent testing is giving you something real to evaluate. One that doesn't is asking for more trust in a market where trust has become expensive.
We'll keep tracking the vendors that remain, and we'll keep noting when something changes. That's the honest milligram version of what happened here — and, as far as we can tell, it's what actually happened.
If we've gotten something wrong or if new information comes out, we'll update this. Corrections go to editor@peptidepricelab.com.